Please assess the completion status of the following clinical trial:

Trial Title: Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 months (365 to 400 days) on the day of inclusion~* Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg~* Informed consent form has been signed and dated by the parent(s) or other legally authorized representative~* Subject and parent/legal representative are able to attend all scheduled visits and to comply with all trial procedures~* Group 1: Subject has received 3 primary vaccination doses of Pediacel as per routine immunization schedule~* Group 3: Subject has received two doses of MenC vaccine at approximately 2 and 4 months of age as per Alberta immunization schedule.~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination(s), which may be received at least two weeks before study vaccines~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination~* Previous vaccination against Meningococcal disease OR~* Subject has previously received only one dose of MenC vaccine, or more than two doses of MenC vaccine, or two doses of MenC vaccine with the most recent dose received in the past 6 months~* Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* Personal or maternal seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, as reported by the parent/legal representative~* History of documented invasive meningococcal disease~* At high risk for meningococcal disease during the trial~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances~* History of contraindication to receipt of pertussis-containing vaccine~* Thrombocytopenia, as reported by the parent/legal representative, contraindicating intramuscular vaccination~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination~* History of seizures~* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion~* History of Guillain-Barré Syndrome.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Menactra® Vaccine Group (Type: EXPERIMENTAL): Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
- Menjugate® Vaccine Group (Type: ACTIVE_COMPARATOR): Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete